MétaCan
Menu
Back to cohort
Record W2978840913 · doi:10.1016/j.molmet.2019.09.010

Glucagon-like peptide 1 (GLP-1)

2019· review· en· W2978840913 on OpenAlexafffund
Timo D. Müller, Brian Finan, Stephen R. Bloom, David A. D’Alessio, Daniel J. Drucker, Peter R. Flatt, Andreas Fritsche, Fiona M. Gribble, Harvey J. Grill, Joel F. Habener, Jens J. Holst, Wolfgang Langhans, Juris J. Meier, Michael A. Nauck, Diego Pérez–Tilve, Alessandro Pocai, Frank Reimann, Darleen A. Sandoval, Thue W. Schwartz, Randy J. Seeley, Kerstin Stemmer, Mads Tang‐Christensen, Stephen C. Woods, Richard D. DiMarchi, M. Tschöp

Bibliographic record

VenueMolecular Metabolism · 2019
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsLunenfeld-Tanenbaum Research InstituteUniversity of Toronto
FundersEuropean Research CouncilBERLIN-CHEMIECanadian Institutes of Health ResearchMerck Sharp and DohmeMedical Research CouncilJohnson and JohnsonServierNovo NordiskNational Institute for Health and Care ResearchNovo Nordisk FondenDeutsche ForschungsgemeinschaftZafgenIndiana UniversityBanting and Best Diabetes Centre, University of TorontoWellcome TrustAlexander von Humboldt-StiftungNovartis PharmaHelmholtz AssociationNovartisMerck KGaANational Institute of Diabetes and Digestive and Kidney DiseasesSanofiMerckPfizerAstraZenecaEli Lilly and CompanyBoehringer Ingelheim
KeywordsGlucagon-like peptide-1Glucagon-like peptide-2GlucagonProglucagonIncretinPeptideChemistryInternal medicineDiabetes mellitusEndocrinologyMedicineInsulinBiochemistryType 2 diabetes

Abstract

fetched live from OpenAlex

BACKGROUND: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. SCOPE OF REVIEW: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. MAJOR CONCLUSIONS: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.004
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0040.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.319
Teacher spread0.283 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1,738
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueMolecular MetabolismSame topicDiabetes Treatment and ManagementFrench-language works237,207